<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> elicits a progressive vascular dysfunction, which contributes to the evolution of brain injury </plain></SENT>
<SENT sid="1" pm="."><plain>Thrombolysis with tissue plasminogen activator (tPA) promotes adverse vascular events that limit the therapeutic window of <z:hpo ids='HP_0001297'>stroke</z:hpo> to three hours </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="52726">Proteasome inhibitors</z:chebi> reduce vascular thrombotic and inflammatory events, and consequently protect vascular function </plain></SENT>
<SENT sid="3" pm="."><plain>The present study evaluated the neuroprotective effect of <z:chebi fb="0" ids="52717">bortezomib</z:chebi>, a potent and selective inhibitor of the proteasome, alone and in combination with delayed thrombolytic therapy on a rat model of embolic focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment with <z:chebi fb="0" ids="52717">bortezomib</z:chebi> reduces adverse cerebrovascular events including secondary <z:mp ids='MP_0005048'>thrombosis</z:mp>, <z:mp ids='MP_0001845'>inflammatory responses</z:mp>, and blood brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) disruption, and hence reduces <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and neurological functional deficit when administrated within 4 h after <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Combination of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> and tPA extends the thrombolytic window for <z:hpo ids='HP_0001297'>stroke</z:hpo> to 6 h, which is associated with the improvement of vascular patency and integrity </plain></SENT>
<SENT sid="6" pm="."><plain>Real time RT-PCR of endothelial cells isolated by laser-capture microdissection from brain tissue and Western blot analysis showed that <z:chebi fb="0" ids="52717">bortezomib</z:chebi> upregulates endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (eNOS) expression and blocks NF-kappaB activation </plain></SENT>
<SENT sid="7" pm="."><plain>These results demonstrate that <z:chebi fb="0" ids="52717">bortezomib</z:chebi> promotes eNOS dependent vascular protection, and reduces NF-kappaB dependent vascular disruption, <z:hpo ids='HP_0000001'>all</z:hpo> of which may contribute to neuroprotection after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>